Exelixis, Inc. (NASDAQ:EXEL) – Investment analysts at Oppenheimer issued their Q2 2019 earnings per share estimates for Exelixis in a report issued on Wednesday, February 13th. Oppenheimer analyst S. Tuerkcan anticipates that the biotechnology company will post earnings of $0.17 per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $31.00 price target on the stock. Oppenheimer also issued estimates for Exelixis’ Q3 2019 earnings at $0.15 EPS, FY2019 earnings at $0.69 EPS, FY2020 earnings at $1.04 EPS, FY2021 earnings at $1.11 EPS and FY2022 earnings at $1.58 EPS.

EXEL has been the subject of several other research reports. ValuEngine cut Exelixis from a “hold” rating to a “sell” rating in a research note on Saturday, January 19th. BidaskClub cut Exelixis from a “buy” rating to a “hold” rating in a research note on Saturday, January 19th. Piper Jaffray Companies decreased their price target on Exelixis from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 5th. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Finally, Zacks Investment Research cut Exelixis from a “buy” rating to a “hold” rating in a research note on Monday, February 11th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. Exelixis currently has an average rating of “Hold” and an average price target of $27.25.

NASDAQ:EXEL opened at $22.26 on Friday. Exelixis has a 1 year low of $13.42 and a 1 year high of $29.94. The firm has a market capitalization of $6.67 billion, a PE ratio of 15.57, a price-to-earnings-growth ratio of 1.42 and a beta of 2.21. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 12th. The biotechnology company reported $0.37 EPS for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.14. The firm had revenue of $228.60 million during the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a return on equity of 56.67% and a net margin of 80.95%. The firm’s revenue was up 90.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.12 EPS.

Several institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC lifted its holdings in shares of Exelixis by 1,903.2% in the fourth quarter. Advisory Services Network LLC now owns 9,515 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 9,040 shares during the period. Amalgamated Bank lifted its holdings in shares of Exelixis by 60.1% in the fourth quarter. Amalgamated Bank now owns 68,537 shares of the biotechnology company’s stock valued at $1,348,000 after buying an additional 25,740 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Exelixis by 97.0% in the fourth quarter. Public Employees Retirement System of Ohio now owns 263,514 shares of the biotechnology company’s stock valued at $5,183,000 after buying an additional 129,749 shares during the period. Legal & General Group Plc lifted its holdings in shares of Exelixis by 5.7% in the fourth quarter. Legal & General Group Plc now owns 345,180 shares of the biotechnology company’s stock valued at $6,790,000 after buying an additional 18,567 shares during the period. Finally, Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Exelixis by 181.7% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 62,460 shares of the biotechnology company’s stock valued at $1,228,000 after buying an additional 40,291 shares during the period. Institutional investors and hedge funds own 78.28% of the company’s stock.

In other news, Director Alan M. Garber sold 11,250 shares of the company’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $23.00, for a total value of $258,750.00. Following the completion of the sale, the director now owns 72,579 shares in the company, valued at $1,669,317. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Michael Morrissey sold 40,000 shares of the company’s stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $22.39, for a total value of $895,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 528,307 shares of company stock valued at $11,422,347. Company insiders own 4.80% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: Cost of Equity For A Business, Investors

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.